MYGN - Myriad Genetics Inc Company Long-Term Liabilities

Public company logo of Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (MYGN) generates revenue from molecular research, offering high-margin genetic screenings for therapy and family planning. Its status as a recognized pioneer in cancer diagnostics ensures physician trust in the brand. Business efficiency is bolstered by the ability to scale test panels using its accumulated data sets. This price chart confirms these metrics, where the debt load stands at 0.20, reflecting the financial standing of an industry leader.

myriad.com (MYGN) Company Long-Term Debt: for the period 07/04/2022 - 10/30/2026

Myriad Genetics Corp (MYGN) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price myriad.com|MYGN - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Myriad Genetics|MYGN - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Myriad Genetics|MYGN - Company Book Value|Market Value to Book Value myriad.com|MYGN - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Myriad Genetics, Inc.|MYGN - Long-Term Debt to Capital|Short-Term Debt to Capital Myriad|MYGN - Company Debts|Debt to Book Value Ratio Myriad Genetics|MYGN - Company Long-Term Debts|Company Short-Term Debts Myriad Genetics|Quick Liquidity myriad.com
- earnings and market multiples details:
MYGN - Net Income
Analysis of all company metrics:myriad.com - MYGN
Brand item of Myriad Genetics Corp

Assessing the reliability of equity assets begins with an analysis of the debt load, where long-term liabilities measure the total of loans with maturities exceeding one year used to finance capital expenditures. The trend in long-term loans and borrowings for Myriad Genetics, Inc. (MYGN) reflects the company's ability to sustain strategic development amid risks of reduced insurance reimbursements and competitive pressure within the genetics sector.

Who Myriad Genetics, Inc. competes with

CAI: Company Long-Term Indebtedness|Guardant Health - Company Long-Term Debts|Veracyte Inc (VCYT) - Company Long-Term Liabilities|CELC: Company Long-Term Debts|Long-Term Debt GRAIL Bio (GRAL)|Company Long-Term Debt Castle Biosciences|BNR: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities VNRX (VolitionRx Limited)|BDSX (Biodesix Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts PRPO (Precipio, Inc)|Company Long-Term Debts Check-Cap Ltd CHEK|MYNZ - Company Long-Term Debt|OCX (oncocyte.com) - Company Long-Term Indebtedness